| 0 |
HUMAN ANTI-MOUSE ANTIBODY POSITIVE |
2 |
0.1176 |
| 1 |
MYXOMA |
1 |
0.0714 |
| 2 |
URINE IODINE INCREASED |
1 |
0.0417 |
| 3 |
RADIOISOTOPE SCAN ABNORMAL |
20 |
0.0283 |
| 4 |
NEUROBLASTOMA RECURRENT |
5 |
0.0246 |
| 5 |
FALSE POSITIVE INVESTIGATION RESULT |
3 |
0.0030 |
| 6 |
NEUROBLASTOMA |
1 |
0.0026 |
| 7 |
URETERIC STENOSIS |
2 |
0.0025 |
| 8 |
NUTRITIONAL CONDITION ABNORMAL |
1 |
0.0014 |
| 9 |
FALSE NEGATIVE INVESTIGATION RESULT |
1 |
0.0014 |
| 10 |
HEMIANOPIA HOMONYMOUS |
1 |
0.0014 |
| 11 |
ANTIBODY TEST POSITIVE |
2 |
0.0012 |
| 12 |
PREMATURE MENOPAUSE |
1 |
0.0011 |
| 13 |
HYPOPERFUSION |
1 |
0.0010 |
| 14 |
ELECTROCARDIOGRAM T WAVE ABNORMAL |
1 |
0.0006 |
| 15 |
OPTIC ATROPHY |
1 |
0.0006 |
| 16 |
MUCOSAL INFLAMMATION |
14 |
0.0005 |
| 17 |
MOTION SICKNESS |
1 |
0.0005 |
| 18 |
CANCER PAIN |
1 |
0.0004 |
| 19 |
HYDRONEPHROSIS |
2 |
0.0003 |
| 20 |
THERAPY PARTIAL RESPONDER |
4 |
0.0003 |
| 21 |
EPIGASTRIC DISCOMFORT |
1 |
0.0003 |
| 22 |
SUSPECTED COUNTERFEIT PRODUCT |
1 |
0.0003 |
| 23 |
METASTATIC NEOPLASM |
1 |
0.0002 |
| 24 |
NO ADVERSE EVENT |
41 |
0.0002 |
| 25 |
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME |
2 |
0.0002 |
| 26 |
MYELODYSPLASTIC SYNDROME |
3 |
0.0002 |
| 27 |
HYPERVOLAEMIA |
1 |
0.0002 |
| 28 |
DERMATITIS EXFOLIATIVE |
1 |
0.0002 |
| 29 |
CLOSTRIDIUM DIFFICILE COLITIS |
2 |
0.0002 |
| 30 |
PULMONARY ALVEOLAR HAEMORRHAGE |
1 |
0.0002 |
| 31 |
NEUTROPENIA |
22 |
0.0002 |
| 32 |
WRONG DRUG ADMINISTERED |
1 |
0.0001 |
| 33 |
INABILITY TO AFFORD MEDICATION |
1 |
0.0001 |
| 34 |
INJECTION SITE EXTRAVASATION |
1 |
0.0001 |
| 35 |
FEBRILE NEUTROPENIA |
5 |
0.0001 |
| 36 |
COMPLICATION ASSOCIATED WITH DEVICE |
1 |
0.0001 |
| 37 |
THERAPY NON-RESPONDER |
3 |
0.0001 |
| 38 |
THYROID DISORDER |
1 |
0.0001 |
| 39 |
INCORRECT ROUTE OF PRODUCT ADMINISTRATION |
1 |
0.0001 |
| 40 |
BONE MARROW FAILURE |
1 |
0.0000 |
| 41 |
LIVER FUNCTION TEST INCREASED |
1 |
0.0000 |
| 42 |
ORAL PAIN |
1 |
0.0000 |
| 43 |
RASH ERYTHEMATOUS |
2 |
0.0000 |
| 44 |
INJECTION SITE URTICARIA |
1 |
0.0000 |
| 45 |
PALLOR |
1 |
0.0000 |
| 46 |
RESPIRATORY DISTRESS |
1 |
0.0000 |
| 47 |
SWOLLEN TONGUE |
1 |
0.0000 |
| 48 |
HYPOTHYROIDISM |
1 |
0.0000 |
| 49 |
NEOPLASM PROGRESSION |
1 |
0.0000 |
| 50 |
BURNING SENSATION |
2 |
0.0000 |
| 51 |
INCORRECT ROUTE OF DRUG ADMINISTRATION |
1 |
0.0000 |
| 52 |
CRYING |
1 |
0.0000 |
| 53 |
THROAT IRRITATION |
1 |
0.0000 |
| 54 |
SKIN DISCOLOURATION |
1 |
0.0000 |
| 55 |
HYPOKALAEMIA |
1 |
0.0000 |
| 56 |
PRODUCT USE ISSUE |
4 |
0.0000 |
| 57 |
SYNCOPE |
2 |
0.0000 |
| 58 |
FLUID RETENTION |
1 |
0.0000 |
| 59 |
PRODUCT SUBSTITUTION ISSUE |
1 |
0.0000 |
| 60 |
BONE PAIN |
1 |
0.0000 |
| 61 |
STOMATITIS |
1 |
0.0000 |
| 62 |
FEELING HOT |
1 |
0.0000 |
| 63 |
DRUG INEFFECTIVE |
21 |
0.0000 |
| 64 |
BLOOD PRESSURE DECREASED |
1 |
0.0000 |
| 65 |
PRODUCT QUALITY ISSUE |
2 |
0.0000 |
| 66 |
DYSGEUSIA |
1 |
0.0000 |
| 67 |
EPISTAXIS |
1 |
0.0000 |
| 68 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
0.0000 |
| 69 |
URTICARIA |
2 |
0.0000 |
| 70 |
RENAL IMPAIRMENT |
1 |
0.0000 |
| 71 |
PYREXIA |
4 |
0.0000 |
| 72 |
TACHYCARDIA |
1 |
0.0000 |
| 73 |
FLUSHING |
1 |
0.0000 |
| 74 |
CHEST DISCOMFORT |
1 |
0.0000 |
| 75 |
PLATELET COUNT DECREASED |
1 |
0.0000 |
| 76 |
VOMITING |
4 |
0.0000 |
| 77 |
DISEASE PROGRESSION |
1 |
0.0000 |
| 78 |
HYPERHIDROSIS |
1 |
0.0000 |
| 79 |
DEHYDRATION |
1 |
0.0000 |
| 80 |
FATIGUE |
5 |
0.0000 |
| 81 |
PARAESTHESIA |
1 |
0.0000 |
| 82 |
TREMOR |
1 |
0.0000 |
| 83 |
MYALGIA |
1 |
0.0000 |
| 84 |
ERYTHEMA |
1 |
0.0000 |
| 85 |
ABDOMINAL PAIN UPPER |
1 |
0.0000 |
| 86 |
HYPERTENSION |
1 |
0.0000 |
| 87 |
DECREASED APPETITE |
1 |
0.0000 |
| 88 |
DIZZINESS |
2 |
0.0000 |
| 89 |
WEIGHT DECREASED |
1 |
0.0000 |
| 90 |
COUGH |
1 |
0.0000 |
| 91 |
DYSPNOEA |
2 |
0.0000 |
| 92 |
HEADACHE |
2 |
0.0000 |
| 93 |
PNEUMONIA |
1 |
0.0000 |
| 94 |
NAUSEA |
2 |
0.0000 |
| 95 |
ARTHRALGIA |
1 |
0.0000 |
| 96 |
OFF LABEL USE |
2 |
0.0000 |
| 97 |
MALAISE |
1 |
0.0000 |